Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 11, 2016Annals of Clinical Biochemistry International Journal of Laboratory MedicineOpen Access

High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does anthracycline-containing chemotherapy increase high-sensitive cardiac troponin-I levels compared to non-anthracycline regimens in patients receiving chemotherapy?

Population

84 patients receiving chemotherapy regimens

Comparison

Anthracycline-containing chemotherapy regimen vs Non-anthracycline-containing chemotherapy regimen

Design

Cohort

Follow-up

following five cycles of treatment

Authors

MJMelissa JonesMedpace (United States)POPeter O’GormanMater Misericordiae HospitalCKCatherine M. KellyMater Misericordiae University Hospital

Discussion

Loading...

Member takes

Overview

hs-cTnI may flag early anthracycline injury; hypothesis-generating and should not yet change practice.

Structured PICO

Does anthracycline-containing chemotherapy increase high-sensitive cardiac troponin-I levels compared to non-anthracycline regimens in patients receiving chemotherapy?

P
Population
84 patients receiving chemotherapy regimens
I
Intervention
Anthracycline-containing chemotherapy regimen (n=38)
C
Comparator
Non-anthracycline-containing chemotherapy regimen (n=46)
O
Outcome
Change in serial high-sensitive cardiac troponin-I concentrations from pretreatment levelssurrogate

High-sensitive cardiac troponin-I can detect subclinical cardiomyocyte injury in patients receiving anthracycline chemotherapy, facilitating early identification of cardiotoxicity.

Cite This Study

Jones et al. (2016) studied this question.

synapsesocial.com/papers/6a75438e1646b2abe5035e75https://doi.org/10.1177/0004563216650464

Topics

Cardiomyopathy
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prevention of Anthracycline-Induced Cardiotoxicity2014 · 685 citations
  2. 2Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment2012 · 891 citations
  3. 3National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure2007 · 250 citations
  4. 4Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone2005 · 242 citations
  5. 5Analytical Characteristics of High-Sensitivity Cardiac Troponin Assays2011 · 858 citations